Peplomycin and liblomycin, a new analogues of bleomycin.
Peplomycin, derivative of Bleomycin which was developed because of a lower pulmonary toxicity and broader anti-tumor spectrum in animal study, also showed to be effective in clinical studies on adenocarcinomas such as prostatic cancer, breast cancer, etc. as well as on squamous cell carcinoma and the anti-tumor spectrum were observed to be broader than those of Bleomycin. Further, the combination therapy with other anti-cancer drugs showed higher effectiveness. Clinically lower pulmonary toxicity was also observed. Liblomycin, derivative of Bleomycin having a lipophyllic characteristics, was developed since it showed in animal studies a lower pulmonary toxicity than that of Peplomycin and broader anti-tumor spectrum. At present, this substance is under Phase I study in Japan.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use* / Q000031:analogs & derivatives; D004285:Dogs; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D017663:Peplomycin; D051381:Rats; D014750:Vincristine / Q000008:administration & dosage
D000903:Antibiotics, Antineoplastic; D001761:Bleomycin; D017663:Peplomycin; D014750:Vincristine; C054113:liblomycin; D008727:Methotrexate